These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14989461)

  • 41. Gastroenterological complications of Anderson-Fabry disease.
    Buda P; Książyk J; Tylki-Szymanska A
    Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
    Das AM; Naim HY
    Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.
    Tuttolomondo A
    Curr Pharm Des; 2013; 19(33):5972-3. PubMed ID: 23448458
    [No Abstract]   [Full Text] [Related]  

  • 45. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gaucher disease: new developments in treatment and etiology.
    Harmanci O; Bayraktar Y
    World J Gastroenterol; 2008 Jul; 14(25):3968-73. PubMed ID: 18609679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy for fabry disease: a review of the literature.
    Ruiz de Garibay AP; Solinís MA; Rodríguez-Gascón A
    BioDrugs; 2013 Jun; 27(3):237-46. PubMed ID: 23575647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enzyme replacement therapy in Gaucher's and Fabry's disease.
    Pentchev PG
    Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers in lysosomal storage diseases: a review.
    Cox TM
    Acta Paediatr Suppl; 2005 Mar; 94(447):39-42; discussion 37-8. PubMed ID: 15895710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.
    Hughes DA; Pastores GM
    Wien Med Wochenschr; 2010 Dec; 160(23-24):594-9. PubMed ID: 21221911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vascular complications of Fabry disease: enzyme replacement and other therapies.
    Hughes DA; Mehta AB
    Acta Paediatr Suppl; 2005 Mar; 94(447):28-33; discussion 9-10. PubMed ID: 15895709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gaucher disease: a heterogeneous clinical complex for which effective enzyme replacement has come of age.
    Frenkel EP
    Am J Med Sci; 1993 May; 305(5):331-44. PubMed ID: 8097903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Gaucher's disease: pathogenesis, diagnosis and therapy].
    Pregun I; Tulassay Z
    Orv Hetil; 2004 Sep; 145(37):1883-90. PubMed ID: 15493618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anderson-Fabry disease: developments in diagnosis and treatment.
    Mehta AB
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical features of and recent advances in therapy for Fabry disease.
    Brady RO; Schiffmann R
    JAMA; 2000 Dec; 284(21):2771-5. PubMed ID: 11105184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.